References
Elmezayen HA, Okabe H, Baba Y, Yusa T, Itoyama R, Nakao Y et al. Clinical role of serum programmed death ligand 1 in patients with hepatocellular carcinoma: Where does it come from? Surg Today. 2019. https://doi.org/10.1007/s00595-019-1920-8
Dioguardi N, Grizzi F, Franceschini B, Bossi P, Russo C. Liver fibrosis and tissue architectural change measurement using fractal-rectified metrics and Hurst's exponent. World J Gastroenterol. 2006;12:2187–94.
West GB. The importance of quantitative systemic thinking in medicine. Lancet. 2012;379:1551–9.
Chiriva-Internati M, Grizzi F, Bright RK, Martin Kast W. Cancer immunotherapy: avoiding the road to perdition. J Transl Med. 2004;2:26.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflicts of interest in association with the present study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Grizzi, F., Qehajaj, D., Yiu, D. et al. PD-L1, fibrosis, and immunotherapy in hepatocellular carcinoma: the importance of a scientific method to explore observations and answer questions. Surg Today 50, 1318–1319 (2020). https://doi.org/10.1007/s00595-020-01965-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00595-020-01965-0